Browsing Tag
GLP-1 receptor agonist
9 posts
EC backs higher-dose Wegovy as obesity competition intensifies
Novo Nordisk A/S wins EU approval for 7.2 mg Wegovy. Discover how this shifts obesity competition, reimbursement, and long-term strategy.
Oral GLP-1 race heats up as Structure Therapeutics posts strong ACCESS data for aleniglipron
Find out how Structure Therapeutics’ oral GLP-1 drug aleniglipron delivered double-digit weight loss in the ACCESS trial and what it means for the obesity market.
Innovent Biologics hits 20% weight loss in Phase 3: Will mazdutide become China’s Ozempic?
Mazdutide 9 mg achieves 20.08% weight loss in pivotal Chinese Phase 3 study. Learn what this means for Innovent Biologics’ NDA plans and obesity treatment.
Eli Lilly (NYSE: LLY) to build $3bn Netherlands plant to power global obesity drug supply
Find out how Eli Lilly’s $3 billion Netherlands plant will reshape obesity drug manufacturing and strengthen Europe’s pharma supply chain resilience.
Ascletis doses first obesity patients in U.S. Phase IIa trial of once-monthly GLP-1R depot ASC30
Ascletis (HKEX: 1672) begins dosing in U.S. Phase IIa obesity trial of ASC30, its once-monthly small molecule GLP-1R agonist, with topline data expected Q1 2026.
Lilly’s oral GLP-1 drug orforglipron cuts A1C and body weight in type 2 diabetes Phase 3 trial
Eli Lilly’s once-daily oral GLP-1 therapy orforglipron delivered significant A1C and weight reductions in Phase 3 ACHIEVE-1 trial, with safety aligned to injectables.
Biomea Fusion posts 15% weight loss in primate model as BMF-650 nears IND for oral GLP-1 therapy
Biomea Fusion’s BMF-650 shows 15% weight loss in primates. Find out why investors are watching its IND filing and Phase I trial timeline for obesity treatment.
Gan & Lee Pharmaceuticals begins US Phase 2 trial of bofanglutide for obesity and weight management
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) has initiated its Phase 2 clinical trial of bofanglutide (GZR18)…
Sun Pharmaceutical’s GL0034 study reveals promising obesity treatment outcomes
Sun Pharmaceutical Industries Limited unveiled data from its Phase 1 study of GL0034 (Utreglutide), targeting obesity in adults.…